These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1220346)

  • 1. [The clinical value of the hydroxyproline excretion in 24 hour urine compared to other laboratory diagnostic parameters in ankylopoietic spondylarthritis].
    Behling H; Kahlfuss R; Wessel G; Rössner B
    Z Gesamte Inn Med; 1975 Jan; 30(2):58-62. PubMed ID: 1220346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary excretion of protein and non-protein hydroxyproline in patients with sarcoidosis and interstitial pulmonary fibrosis.
    Podwysocki B; Zwoliński J; Szklarz E
    Mater Med Pol; 1993; 25(1):13-6. PubMed ID: 8412335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
    Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
    J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Urinary hydroxyproline excretion in liver cirrhosis].
    Bretzke G; List A; Stahl E
    Z Gesamte Inn Med; 1978 Mar; 33(5):148-50. PubMed ID: 645148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the usefulness of suction drainage in the treatment of nonspecific bone infections monitored with C-reactive protein].
    Milankov M; Jovanović A; Milicić A; Somer T; Vukadinović S; Savić D
    Med Pregl; 1999; 52(11-12):489-94. PubMed ID: 10748773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Excretion of hydroxyproline in chronic polyarthritis].
    Wessel G; Bretzke G; Bretzke K
    Z Rheumaforsch; 1970; 29(7):203-10. PubMed ID: 4108122
    [No Abstract]   [Full Text] [Related]  

  • 7. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
    Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative characteristics of oxyproline excretion in urine in children with post-burn hypertrophic and keloid scars].
    Kozlov EA; Bagdatlishvili GI; Prozorovskaia NN; Del'vig AA
    Vopr Med Khim; 1991; 37(3):17-9. PubMed ID: 1949673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Collagen metabolism in patients with bone system tumors].
    Balaba TIa; Zatsepin ST; Furtseva LN
    Vopr Med Khim; 1971; 17(4):388-93. PubMed ID: 5317621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein: a marker for disease activity in ankylosing spondylitis and Reiter's syndrome.
    Nashel DJ; Petrone DL; Ulmer CC; Sliwinski AJ
    J Rheumatol; 1986 Apr; 13(2):364-7. PubMed ID: 3723498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Excretion of hydroxyproline in the urine of workers engaged in the production of iron-manganese alloys].
    Misiewicz A
    Med Pr; 1991; 42(5):367-71. PubMed ID: 1808446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [C-reactive protein, leukocyte count and D-dimer monitoring after orthopedic surgery: early diagnosis of infectious or thromboembolic complications. Part one: C-reactive protein and leukocyte count as an aid in diagnosing postoperative infection].
    Codine P; Barbotte E; Denis-Laroque F; Lansac H; Dupetit T; Pradies F; Ricart B; Herisson C
    Ann Readapt Med Phys; 2005 Nov; 48(8):590-7. PubMed ID: 15961180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum hydroxyproline parameter of collagen metabolism (author's transl)].
    Raab W; Pemp W; Schwägerl W
    Wien Klin Wochenschr; 1981 Mar; 93(5):165-70. PubMed ID: 7281690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Red cell system and selected red cell enzymes in men occupationally exposed to mercury vapours].
    Zabiński Z; Rutowski J; Moszczyński P; Dabrowski Z
    Przegl Lek; 2006; 63 Suppl 7():74-83. PubMed ID: 17784549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism.
    Segrest JP; Cunningham LW
    J Clin Invest; 1970 Aug; 49(8):1497-509. PubMed ID: 5431661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of protein malnutrition on the metabolism of dermal collagen in the rat.
    Rao JS; Rao VH
    Ital J Biochem; 1980; 29(1):1-12. PubMed ID: 6769839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
    Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.